On the other hand, POLEM trial aims to assess Avelumab (anti-PD-L1 mAb) treatment following adjuvant 5-FU based chemotherapy in dMMR/MSI-H and/or POLE exonuclease domain mutant CRC tumors [80]. This evidence concerns the gene CD274 and colorectal carcinoma.